3 active not recruiting, 3 recruiting, 2 completed, 1 terminated. 4 Phase 3, 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Active not recruiting 2, Recruiting 2 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow Rhabdomyosarcoma, Embryonal: new trials by email Literature Review of Rhabdomyosarcoma, Embryonal trials Research Report on Rhabdomyosarcoma, Embryonal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma Biopsy Procedure, Bone Scan, Computed Tomography - Embryonal Rhabdomyosarcoma, Fusion-Negative Alveolar Rhabdomyosarcoma | Phase 3 | Recruiting | Children's Oncology Group | 205 | 2022-08-04 | 2026-08-25 |
| A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma | Phase 3 | Active not recruiting | Children's Oncology Group | 113 | 2021-09-14 | 2026-07-30 |
| Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas dinutuximab beta - Bone Sarcoma, Embryonal Rhabdomyosarcoma | Phase 3 | Recruiting | N.N. Petrov National Medical Research Center of Oncology | 40 | 2021-05-20 | 2024-11-01 |
| Genetic Mutational Analysis of Saliva or Buccal Mucosa Samples From Patients With Embryonal or Alveolar Rhabdomyosarcoma Biospecimen Collection, Laboratory Biomarker Analysis, Questionnaire Administration - Alveolar Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma | Active not recruiting | Children's Oncology Group | 900 | 2017-10-23 | 2026-02-06 | |
| Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma Dasatinib, Ganitumab - Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 14 | 2017-07-07 | 2022-04-14 |
| International PPB/DICER1 Registry Pleuropulmonary Blastoma, Sertoli-Leydig Cell Tumor | Recruiting | Children's Hospitals and Clinics of Minnesota | 3400 | 2016-12-06 | 2025-01-30 | |
| Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma Cyclophosphamide, Dactinomycin, Irinotecan Hydrochloride - Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 325 | 2016-06-01 | 2026-10-01 |
| Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma Tumor Purged/CD25 Depleted Lymphocytes, Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine, rhIL-7 - Neuroblastoma, Sarcoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 44 | 2007-06-02 | 2018-06-15 |
| Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Imatinib mesylate - Life Threatening Diseases | Phase 2 | Completed | Novartis Pharmaceuticals | 185 | 2001-02-01 | 2016-11-18 |
Rhabdomyosarcoma, Alveolar (6) · Rhabdomyosarcoma (4) · Neuroblastoma (2) · Sarcoma, Ewing (2) · Adenocarcinoma (1) · Bone Neoplasms (1) · Brenner Tumor (1) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Ductal, Breast (1) · Carcinoma, Renal Cell (1) · Chondrosarcoma (1) · Chordoma (1) · Dermatofibrosarcoma (1) · Disease (1)
Myosarcoma (9) · Neoplasms by Histologic Type (9) · Neoplasms, Connective and Soft Tissue (9) · Neoplasms, Muscle Tissue (9) · Neoplasms (8) · Sarcoma (8) · Rhabdomyosarcoma (5) · Neoplasms by Site (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Glandular and Epithelial (3) · Neoplasms, Nerve Tissue (3) · Neuroectodermal Tumors (3) · Adnexal Diseases (2) · Endocrine System Diseases (2) · Female Urogenital Diseases (2)
Cyclophosphamide (3) · Dactinomycin (3) · Radiation (3) · Radiotherapy (3) · Vincristine (3) · Biopsy (2) · Magnetic Resonance Spectroscopy (2) · Vinorelbine (2) · Dasatinib (1) · Imatinib Mesylate (1) · Irinotecan (1) · Phantoms, Imaging (1) · Receptor Protein-Tyrosine Kinases (1) · Sirolimus (1) · Specimen Handling (1)
Children's Oncology Group (3) · National Cancer Institute (NCI) (3) · Children's Hospitals and Clinics of Minnesota (1) · N.N. Petrov National Medical Research Center of Oncology (1) · Novartis Pharmaceuticals (1)
United States (7) · Australia (3) · Canada (3) · New Zealand (2) · Puerto Rico (2) · Russia (1) · Saudi Arabia (1)
Abha A Gupta (1) · Christine M Heske, M.D. (1) · John Glod, M.D. (1) · Josephine H Haduong (1) · Kris Ann P Schultz, MD (1) · Michael Heinrich, MD (1) · Philip Lupo (1) · Svetlana Kulyova, MD, Phd (1) · Wendy Allen-Rhoades (1)
PMID 19451433, PMID 19556464, PMID 25209242, PMID 27441995, PMID 28674120, PMID 29343557, PMID 30178239, PMID 30339877, PMID 30672147, PMID 30677214, PMID 30715996, PMID 30824630, PMID 31296931, PMID 31820118, PMID 31838154, PMID 31952842, PMID 32291395, PMID 32415267, PMID 33119505, PMID 33484847, PMID 33570641, PMID 33630087, PMID 33637876, PMID 33782093, PMID 33875804, PMID 37398992, PMID 38603649, PMID 38936378, PMID 41914453
U10CA180886 (3)